Results from a recent French study based on data from clinical practice indicate that vitamin K antagonists and low-molecular weight heparin are more effective than aspirin in preventing clots during myeloma treatment with the immuno­modu­la­tory drugs thalidomide or Revlimid.

Specifically, 7 percent of patients receiving aspirin developed blood clots, compared to 3 percent of patients receiving low-molecular weight heparin and 0 percent receiving a vitamin K antagonist such as warfarin (Coumadin).

Interestingly, the rate of blood clot formation was lowest among patients with the highest risk of developing blood clots, which the …